PFE
PFIZER INC
$26.21
+0.15%
$149.4B
No data for this timeframe.
Vol
Market Cap$149.4B
Cap SizeLarge Cap
Analyst ConsensusHold (42%)
Inst. Holders50 funds
Inst. Value$66.6B
Inst. Activity28 buys / 22 sells
Insider Activity0B / 1S
Insider Net $-$51.4K
Reddit Sentiment67° Warm
SEC Reports7
Congressional3 trades
Recent Activity
Aug 17, 2026
fda_pdufa
PDUFA: PFE — Padcev in muscle-invasive bladder cancer (MIBC) — 2026-08-17
FDA target action date 2026-08-17 for PFE (PFIZER INC). Drug: Padcev. Indication: muscle-invasive bl
Jun 9, 2026
Insider
DAMICO JENNIFER B. sold 2,000 shares
SVP & Controller @ $25.70 ($51.4K)
Jun 9, 2026
Event
MORPHINE SULFATE
Unavailable: Discontinuation of the manufacture of the drug (Discontinuation of the manufacture of t
May 29, 2026
Insider
BOURLA ALBERT was granted 23 shares
Chairman & CEO @ $26.18 ($602.14)
May 16, 2026
SEC
CICC initiates PFE at Outperform with $33 PT (+27%) — a bullish call on a stock consensus largely rates as a Hold
ANALYST-UPGRADE — Impact 2/10
May 15, 2026
Insider
BOURLA ALBERT was granted 24 shares
Chairman & CEO @ $25.33 ($607.92)
Apr 16, 2026
SEC
CICC initiates PFE at Outperform with $33 PT — +15.6% upside vs. consensus mean
ANALYST-UPGRADE — Impact 3/10
Apr 16, 2026
SEC
Argus Research upgraded PFE from Hold to Buy with a $35 price target, representing 22.6% upside from the current $28.55.
ANALYST-UPGRADE — Impact 7/10
Price Targets
$29.19
+11.4% upside
Buy
Current $26.21
Low $24.00
Median $28.00
High $36.00
27 analysts
$24.00
$36.00
Analyst Ratings
6Strong Buy
9Buy
18Hold
2Sell
1Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 10, 2026 | RBC Capital | UPGRADE | Underperform → Sector Perform |
| Apr 29, 2026 | Citigroup | MAINTAIN | Neutral → Neutral |
| Apr 20, 2026 | RBC Capital | REITERATE | Underperform → Underperform |
| Apr 16, 2026 | CICC | INITIATE | Outperform |
| Apr 13, 2026 | UBS | MAINTAIN | Neutral → Neutral |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $0.68 | $0.61 — $0.76 | -13% YoY | 18 |
| Next Q | $0.85 | $0.65 — $0.96 | -2% YoY | 18 |
| Current FY | $2.96 | $2.80 — $3.12 | -8% YoY | 26 |
| Next FY | $2.83 | $2.43 — $3.10 | -4% YoY | 26 |
Latest Reports
BULLISH
ANALYST-UPGRADE
2/10
CICC initiates PFE at Outperform with $33 PT (+27%) — a bullish call on a stock consensus largely rates as a Hold
May 16, 2026
BULLISH
ANALYST-UPGRADE
7/10
Argus Research upgraded PFE from Hold to Buy with a $35 price target, representing 22.6% upside from the current $28.55.
Apr 16, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| Cresset Asset Management, LLC | — | — |
| BlackRock, Inc. | $14.0B | — |
| VANGUARD CAPITAL MANAGEMENT LLC | $10.4B | — |
| STATE STREET CORP | $8.5B | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $3.3B | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 9, 2026 | DAMICO JENNIFER | SELL | $51.4K |
| May 29, 2026 | BOURLA ALBERT | A | $602.14 |
| May 15, 2026 | BOURLA ALBERT | A | $607.92 |
| Apr 23, 2026 | Taraporevala Cyrus | A | $205.0K |
| Apr 23, 2026 | Quincey James | A | $205.0K |
Reddit Sentiment
67°
Warm
Bearish
Neutral
Bullish
Congressional Trades
3 members: 3 buys, 0 sells
| Member | Party | Type | Amount |
|---|---|---|---|
| Ro Khanna | D | BUY | $1,001 - $15,000 |
| Gilbert Cisneros | D | BUY | $1,001 - $15,000 |
| Susan Collins | R | BUY | $15,001 - $50,000 |
50 institutional holders with $66.6B total value (2,369,814,611 shares) as of 2026-Q1. Top holders: Cresset, BlackRock,, VANGUARD. Net buying activity: 28 institutions added/increased vs 22 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | Cresset Asset Management, LLC | — | $0.00 | 0.0% | — |
| 2 | BlackRock, Inc. | 498,257,550 | $14.0B | 21.0% | — |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 369,430,012 | $10.4B | 15.6% | — |
| 4 | STATE STREET CORP | 301,589,865 | $8.5B | 12.7% | — |
| 5 | VANGUARD PORTFOLIO MANAGEMENT LLC | 116,734,695 | $3.3B | 4.9% | — |
| 6 | MORGAN STANLEY | 92,685,370 | $2.6B | 3.9% | — |
| 7 | MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 56,911,830 | $1.6B | 2.4% | — |
| 8 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 51,891,636 | $1.5B | 2.2% | — |
| 9 | WELLINGTON MANAGEMENT GROUP LLP | 49,916,961 | $1.4B | 2.1% | — |
| 10 | GOLDMAN SACHS GROUP INC | 47,105,556 | $1.3B | 2.0% | — |
| 11 | BANK OF AMERICA CORP /DE/ | 46,545,479 | $1.3B | 2.0% | — |
| 12 | Legal & General Group Plc | 43,505,563 | $1.2B | 1.8% | — |
| 13 | Amundi | 40,825,470 | $1.1B | 1.7% | — |
| 14 | DIMENSIONAL FUND ADVISORS LP | 36,422,799 | $1.0B | 1.5% | — |
| 15 | ROYAL BANK OF CANADA | 34,155,840 | $959.1M | 1.4% | — |
| 16 | VANGUARD FIDUCIARY TRUST CO | 32,001,259 | $898.6M | 1.4% | — |
| 17 | DEUTSCHE BANK AG\ | 31,428,987 | $882.5M | 1.3% | — |
| 18 | FRANKLIN RESOURCES INC | 28,341,834 | $795.8M | 1.2% | — |
| 19 | Invesco Ltd. | 27,941,976 | $784.6M | 1.2% | — |
| 20 | DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main | 27,076,800 | $755.3M | 1.1% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MARSHALL WACE, LLP | ADD | 12,661,914 | 16,082,788 | +27.0% | $451.6M | 2026-Q1 |
| Neuberger Berman Group LLC | ADD | 7,361,654 | 9,693,119 | +31.7% | $272.1M | 2026-Q1 |
| Artemis Investment Management LLP | ADD | 5,609,880 | 7,392,508 | +31.8% | $207.6M | 2026-Q1 |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | ADD | 4,245,354 | 6,989,299 | +64.6% | $196.3M | 2026-Q1 |
| CANADA PENSION PLAN INVESTMENT BOARD | ADD | 5,303,155 | 6,777,646 | +27.8% | $190.3M | 2026-Q1 |
| DIAMOND HILL CAPITAL MANAGEMENT INC | TRIM | 9,439,267 | 6,108,570 | -35.3% | $171.5M | 2026-Q1 |
| Assenagon Asset Management S.A. | DOUBLED | 2,063,459 | 6,073,170 | +194.3% | $170.5M | 2026-Q1 |
| FIFTH THIRD BANCORP | ADD | 2,590,275 | 4,536,233 | +75.1% | $127.4M | 2026-Q1 |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | TRIM | 7,195,296 | 4,526,927 | -37.1% | $127.1M | 2026-Q1 |
| Point72 Asset Management, L.P. | ADD | 3,305,692 | 4,365,063 | +32.0% | $122.6M | 2026-Q1 |
| JANUS HENDERSON GROUP PLC | TRIM | 8,786,084 | 3,223,714 | -63.3% | $90.5M | 2026-Q1 |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | ADD | 2,324,745 | 3,055,419 | +31.4% | $85.8M | 2026-Q1 |
| CIBC WORLD MARKET INC. | ADD | 1,887,081 | 2,888,310 | +53.1% | $81.1M | 2026-Q1 |
| SOUND SHORE MANAGEMENT INC /CT/ | NEW | — | 2,870,421 | — | $80.6M | 2026-Q1 |
| Cullen Capital Management, LLC | ADD | 2,097,331 | 2,693,507 | +28.4% | $75.6M | 2026-Q1 |
| M&T BANK CORP | DOUBLED | 240,613 | 2,660,449 | +1005.7% | $74.7M | 2026-Q1 |
| CWM, LLC | ADD | 1,625,379 | 2,111,686 | +29.9% | $59.3M | 2026-Q1 |
| NATIXIS | TRIM | 5,629,824 | 1,912,234 | -66.0% | $53.7M | 2026-Q1 |
| TORONTO DOMINION BANK | TRIM | 3,234,336 | 1,713,006 | -47.0% | $48.1M | 2026-Q1 |
| Cerity Partners LLC | TRIM | 3,187,455 | 1,698,192 | -46.7% | $47.7M | 2026-Q1 |
| PINEBRIDGE INVESTMENTS LLC | DOUBLED | 433,331 | 1,666,733 | +284.6% | $46.8M | 2026-Q1 |
| TEACHER RETIREMENT SYSTEM OF TEXAS | TRIM | 2,509,842 | 1,469,652 | -41.4% | $41.3M | 2026-Q1 |
| FJARDE AP-FONDEN /FOURTH SWEDISH NATIONAL PENSION FUND | ADD | 921,771 | 1,441,271 | +56.4% | $40.5M | 2026-Q1 |
| Mediolanum International Funds Ltd | DOUBLED | 152,607 | 1,373,098 | +799.8% | $38.1M | 2026-Q1 |
| CREDIT AGRICOLE S A | TRIM | 3,106,796 | 1,186,021 | -61.8% | $33.3M | 2026-Q1 |
22 unique insiders with 50 transactions. Net insider value: -$51.4K ($0.00 bought, $51.4K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 9, 2026 | DAMICO JENNIFER B. | SVP & Controller | SELL | 2,000 | $25.70 | $51.4K |
| May 29, 2026 | BOURLA ALBERT | Chairman & CEO | AWARD | 23 | $26.18 | $602.14 |
| May 15, 2026 | BOURLA ALBERT | Chairman & CEO | AWARD | 24 | $25.33 | $607.92 |
| Apr 23, 2026 | Taraporevala Cyrus | Director | AWARD | 7,686.539 | $26.67 | $205.0K |
| Apr 23, 2026 | Quincey James | Director | AWARD | 7,686.539 | $26.67 | $205.0K |
| Apr 23, 2026 | SMITH JAMES C | Director | AWARD | 7,686.539 | $26.67 | $205.0K |
| Apr 23, 2026 | NARAYEN SHANTANU | Director | AWARD | 7,686.539 | $26.67 | $205.0K |
| Apr 23, 2026 | BLAYLOCK RONALD E | Director | AWARD | 7,686.539 | $26.67 | $205.0K |
| Apr 23, 2026 | Buckley Mortimer J | Director | AWARD | 7,686.539 | $26.67 | $205.0K |
| Apr 23, 2026 | Echevarria Joseph | Director | AWARD | 7,686.539 | $26.67 | $205.0K |
| Apr 23, 2026 | Desmond-Hellmann Susan | Director | AWARD | 7,686.539 | $26.67 | $205.0K |
| Apr 23, 2026 | NORA JOHNSON SUZANNE M | Director | AWARD | 7,686.539 | $26.67 | $205.0K |
| Apr 23, 2026 | Gottlieb Scott | Director | AWARD | 7,686.539 | $26.67 | $205.0K |
| Apr 23, 2026 | LITTMAN DAN R. | Director | AWARD | 7,686.539 | $26.67 | $205.0K |
| Apr 15, 2026 | BOURLA ALBERT | Chairman & CEO | AWARD | 22 | $27.19 | $598.18 |
| Apr 14, 2026 | BOURLA ALBERT | Chairman & CEO | AWARD | 911 | $27.11 | $24.7K |
| Mar 31, 2026 | BOURLA ALBERT | Chairman & CEO | AWARD | 21 | $28.08 | $589.68 |
| Mar 27, 2026 | Buckley Mortimer J | Director | AWARD | 1,386.834 | $27.04 | $37.5K |
| Mar 27, 2026 | NARAYEN SHANTANU | Director | AWARD | 1,849.112 | $27.04 | $50.0K |
| Mar 27, 2026 | Echevarria Joseph | Director | AWARD | 1,710.429 | $27.04 | $46.3K |
| Mar 27, 2026 | Quincey James | Director | AWARD | 1,433.062 | $27.04 | $38.7K |
| Mar 27, 2026 | SMITH JAMES C | Director | AWARD | 1,664.201 | $27.04 | $45.0K |
| Mar 27, 2026 | Taraporevala Cyrus | Director | AWARD | 1,386.834 | $27.04 | $37.5K |
| Mar 13, 2026 | BOURLA ALBERT | Chairman & CEO | AWARD | 1,630 | $26.58 | $43.3K |
| Mar 4, 2026 | DAMICO JENNIFER B. | SVP & Controller | TAX W/H | 826 | $26.62 | $22.0K |
| Mar 3, 2026 | DAMICO JENNIFER B. | SVP & Controller | AWARD | 16,311 | — | — |
| Mar 3, 2026 | DAMICO JENNIFER B. | SVP & Controller | AWARD | 22,638 | — | — |
| Mar 3, 2026 | de Germay Alexandre | Executive Vice President | AWARD | 194,883 | — | — |
| Mar 3, 2026 | Denton David M | Chief Financial Officer & EVP | AWARD | 216,537 | — | — |
| Mar 3, 2026 | SAHNI PAYAL | Executive Vice President | AWARD | 108,268 | — | — |
| Mar 3, 2026 | Baum Andrew | Executive Vice President | AWARD | 303,151 | — | — |
| Mar 3, 2026 | Fonseca Lidia | Executive Vice President | AWARD | 82,284 | — | — |
| Mar 3, 2026 | LANKLER DOUGLAS M | Executive Vice President | AWARD | 194,883 | — | — |
| Mar 3, 2026 | BOURLA ALBERT | Chairman & CEO | AWARD | 708,666 | — | — |
| Mar 3, 2026 | McDermott Michael | Executive Vice President | AWARD | 151,576 | — | — |
| Mar 3, 2026 | BOSHOFF CHRISTOFFEL | President, R&D | AWARD | 259,844 | — | — |
| Mar 3, 2026 | MALIK AAMIR | Executive Vice President | AWARD | 194,883 | — | — |
| Feb 27, 2026 | DAMICO JENNIFER B. | SVP & Controller | TAX W/H | 655 | $27.65 | $18.1K |
| Feb 26, 2026 | McDermott Michael | Executive Vice President | TAX W/H | 3,503 | $27.10 | $94.9K |
| Feb 25, 2026 | BOSHOFF CHRISTOFFEL | President, R&D | AWARD | 13,383 | — | — |
| Feb 25, 2026 | SAHNI PAYAL | Executive Vice President | EXERCISE | 56,888 | $33.82 | $1.9M |
| Feb 25, 2026 | Fonseca Lidia | Executive Vice President | EXERCISE | 56,888 | $33.82 | $1.9M |
| Feb 25, 2026 | LANKLER DOUGLAS M | Executive Vice President | EXERCISE | 122,907 | $33.82 | $4.2M |
| Feb 25, 2026 | BOURLA ALBERT | Chairman & CEO | EXERCISE | 491,626 | $33.82 | $16.6M |
| Feb 25, 2026 | DAMICO JENNIFER B. | SVP & Controller | EXERCISE | 17,558 | $33.82 | $593.8K |
| Feb 25, 2026 | McDermott Michael | Executive Vice President | EXERCISE | 37,925 | $33.82 | $1.3M |
| Feb 23, 2026 | DAMICO JENNIFER B. | SVP & Controller | TAX W/H | 419 | $27.06 | $11.3K |
| Feb 23, 2026 | BOSHOFF CHRISTOFFEL | President, R&D | TAX W/H | 816 | $27.06 | $22.1K |
| Feb 12, 2026 | BOURLA ALBERT | Chairman & CEO | AWARD | 2,883 | $27.47 | $79.2K |
| Jan 30, 2026 | BOSHOFF CHRISTOFFEL | President, R&D | TAX W/H | 12,887 | $26.44 | $340.7K |
7 SEC filing reports analyzed. Sentiment: 3 bullish, 0 bearish, 0 mixed, 4 neutral. Avg impact: 3.0/10.
BULLISH
ANALYST-UPGRADE
2/10
CICC initiates PFE at Outperform with $33 PT (+27%) — a bullish call on a stock consensus largely rates as a Hold
May 16, 2026
BULLISH
ANALYST-UPGRADE
7/10
Argus Research upgraded PFE from Hold to Buy with a $35 price target, representing 22.6% upside from
Apr 16, 2026
BULLISH
ANALYST-UPGRADE
3/10
CICC initiates PFE at Outperform with $33 PT — +15.6% upside vs. consensus mean
Apr 16, 2026
NEUTRAL
ANALYST-UPGRADE
2/10
RBC Capital upgrades PFE to Sector Perform — PT $25 (-2.7%)
Jun 10, 2026
NEUTRAL
ANALYST-UPGRADE
1/10
Argus Research upgrades PFE to Buy — PT $35 (+35%) amid 8-firm cluster; consensus remains cautious
May 16, 2026
NEUTRAL
8-K
4/10
Pfizer reported Q1 2026 Adjusted diluted EPS of $0.75, beating the $0.72 consensus by 4.2%, on reven
May 5, 2026
NEUTRAL
DEFA14A
2/10
Analysis based on filing metadata only — document content was unavailable
Mar 12, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Hold (42% buy). Based on 36 analysts: 6 strong buy, 9 buy, 18 hold, 2 sell, 1 strong sell.
Analyst Price Targets
$29.19 mean target
+11.4% upside
Buy (2.41)
$24.00 Low
$36.00 High
| Metric | Value |
|---|---|
| Current Price | $26.21 |
| Target Low | $24.00 |
| Target Mean | $29.19 |
| Target Median | $28.00 |
| Target High | $36.00 |
| # Analysts | 27 |
| Recommendation | Buy (2.41) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.68 | $0.61 | $0.76 | -13.0% | -0.3% | 6↑ 8↓ | $14.4B | -1.6% | 18 |
| Next Q 2026-09-30 |
$0.85 | $0.65 | $0.96 | -2.5% | -0.2% | 7↑ 7↓ | $16.1B | -3.0% | 18 |
| Current FY 2026-12-31 |
$2.96 | $2.80 | $3.12 | -8.1% | -0.2% | 11↑ 8↓ | $61.7B | -1.4% | 26 |
| Next FY 2027-12-31 |
$2.83 | $2.43 | $3.10 | -4.4% | -0.5% | 12↑ 7↓ | $59.3B | -3.8% | 26 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $0.679 | |
| 7d ago | $0.680 | -0.002 |
| 30d ago | $0.681 | -0.002 |
| 60d ago | $0.683 | -0.005 |
| 90d ago | $0.702 | -0.023 |
12 analyst firms have rated this stock: 2 upgrades, 0 downgrades, 3 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 10, 2026 | RBC Capital | UPGRADE | Underperform | Sector Perform |
| Apr 29, 2026 | Citigroup | MAINTAIN | Neutral | Neutral |
| Apr 20, 2026 | RBC Capital | REITERATE | Underperform | Underperform |
| Apr 16, 2026 | CICC | INITIATE | — | Outperform |
| Apr 13, 2026 | UBS | MAINTAIN | Neutral | Neutral |
| Apr 10, 2026 | Morgan Stanley | MAINTAIN | Equal-Weight | Equal-Weight |
| Apr 9, 2026 | B of A Securities | MAINTAIN | Neutral | Neutral |
| Mar 24, 2026 | Guggenheim | MAINTAIN | Buy | Buy |
| Mar 17, 2026 | HSBC | MAINTAIN | Buy | Buy |
| Mar 2, 2026 | Argus Research | UPGRADE | Hold | Buy |
| Feb 25, 2026 | RBC Capital | INITIATE | — | Underperform |
| Feb 20, 2026 | Barclays | INITIATE | — | Underweight |
| Feb 9, 2026 | Freedom Broker | MAINTAIN | Buy | Buy |
| Feb 4, 2026 | Cantor Fitzgerald | REITERATE | Neutral | Neutral |
| Jan 27, 2026 | Cantor Fitzgerald | MAINTAIN | Neutral | Neutral |
| Dec 17, 2025 | Morgan Stanley | MAINTAIN | Equal-Weight | Equal-Weight |
| Dec 15, 2025 | B of A Securities | MAINTAIN | Neutral | Neutral |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 6 | 9 | 18 | 2 | 1 | 42% | |
| May 1, 2026 | 5 | 11 | 17 | 2 | 1 | 44% | |
| Apr 1, 2026 | 6 | 9 | 17 | 2 | 1 | 43% | |
| Mar 1, 2026 | 5 | 9 | 18 | 2 | 1 | 40% | |
| Feb 1, 2026 | 5 | 10 | 17 | 0 | 1 | 45% | |
| Jan 1, 2026 | 5 | 10 | 17 | 0 | 1 | 45% |
Strong BuyBuyHoldSellStrong Sell
3 members of Congress traded this stock: 3 buys, 0 sells.
Congressional Trades
| Date | Member | Party | Chamber | Type | Amount | Asset | Disclosed |
|---|---|---|---|---|---|---|---|
| Apr 13, 2026 | Ro Khanna | D | HOUSE | BUY | $1,001 - $15,000 | Pfizer Inc | May 13, 2026 (31d) |
| Feb 10, 2026 | Gilbert Cisneros | D | HOUSE | BUY | $1,001 - $15,000 | Pfizer Inc | Mar 10, 2026 (29d) |
| Feb 3, 2026 | Susan Collins | R | SENATE | BUY | $15,001 - $50,000 | Pfizer Inc | Mar 26, 2026 (51d) |
67°
Warm
Bearish
Neutral
Bullish
2 mentions
2 bullish
0 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| May 19, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 19, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
The best stock to buy: $BWXT
▲ 1
💬 0
⚡ 0.5
Calls on Pfizer (PFE) - Good Margin of Safety
▲ 1
💬 1
⚡ 0.0
Aug 17, 2026
fda_pdufa
PDUFA: PFE — Padcev in muscle-invasive bladder cancer (MIBC) — 2026-08-17
FDA target action date 2026-08-17 for PFE (PFIZER INC). Drug: Padcev. Indication: muscle-invasive bladder cancer (MIBC). FDA set PDUFA target action d
Jun 13, 2026
Clinical Trial
Pectoral Nerve Block for Analgesia After Breast Augmentation
Phase Phase 3 — COMPLETED
Jun 13, 2026
Clinical Trial
A Study About Modified RNA Vaccines Against Influenza in Healthy Adults
Phase Phase 2 — COMPLETED
Jun 13, 2026
Clinical Trial
Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)
Phase Phase 3 — COMPLETED
Jun 13, 2026
clinical_trial_readout
Results Pending: Irinotecan (Phase 3) — Completed 64d ago
Trial: Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Smal
Jun 12, 2026
Clinical Trial
Evaluation of the Efficacy of Intra-nasal Sufentanil for Analgesia of Vaso-occlusive Crisis in Sickle-cell Adults.
Phase Phase 3 — TERMINATED
Jun 12, 2026
Clinical Trial
Interscalene Block and Dysfunction Diaphragmatic
Phase Phase 3 — COMPLETED
Jun 12, 2026
short_volume
Short Volume: PFE — 55.3% short (8.0M / 14.5M)
Short: 8,018,610 | Exempt: 48,441 | TRF Vol: 14,495,463 | Short Ratio: 55.3% | Off-exchange volume (dark pool + OTC)
Jun 10, 2026
clinical_trial_readout
Results Pending: Multivalent Pneumococcal Vaccine - Formulation 1 (Phase 2) — Completed 29d ago
Trial: A Study to Learn About the Safety and Immune Response of a New Pneumococcal Vaccine in Adults
Sponsor: Pfizer
Phase: Phase 2 | Completed: 2026-
Jun 9, 2026
FDA
MORPHINE SULFATE
Unavailable: Discontinuation of the manufacture of the drug (Discontinuation of the manufacture of the drug) [Analgesia/Addiction]
Jun 9, 2026
FDA
FENTANYL CITRATE
Limited Availability: Limited Supply Available. Next Delivery and Estimated Recovery: June 2026 (Demand increase for the drug) [Analgesia/Addiction, P
Jun 9, 2026
FDA
DEPO-MEDROL
Limited Availability: Limited Supply Available. Next Delivery: June 2026; Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing
Jun 5, 2026
FDA
HYMPAVZI
Supplemental Approval — Efficacy — MARSTACIMAB-HNCQ — INJECTABLE — SUBCUTANEOUS
Jun 4, 2026
FDA
Premarin
WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, BREAST CANCER and PROBABLE DEMENTIA WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, BREA
Jun 3, 2026
clinical_trial_readout
T-90d Trial Readout: ARV-471 (Phase 2)
Trial: TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Brea
Jun 1, 2026
clinical_trial_readout
T-90d Trial Readout: PF-07220060 + PF-07104091 combination dose escalation (Phase 2)
Trial: A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tum
Jun 1, 2026
short_volume
Short Volume: PFE — 55.4% short (8.9M / 16.0M)
Short: 8,875,058 | Exempt: 57,210 | TRF Vol: 16,014,448 | Short Ratio: 55.4% | Off-exchange volume (dark pool + OTC)
May 27, 2026
clinical_trial_readout
Results Pending: Carboplatin (Phase 2) — Completed 48d ago
Trial: Nadunolimab in Combination With Gemcitabine Plus Carboplatin in Patients With Advanced Triple Negative Breast Cancer.
Sponsor: Cantargia AB
Pha
May 25, 2026
clinical_trial_readout
T-90d Trial Readout: PF-07220060 + PF-07104091 combination dose escalation (Phase 2)
Trial: A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tum
May 18, 2026
dark_pool
Dark Pool: PFE — 26.8M shares, 175,041 trades
Week starting 2026-05-18. Total ATS volume: 26,800,654 shares across 175,041 trades.
May 13, 2026
clinical_trial_readout
Results Pending: Irinotecan (Phase 3) — Completed 33d ago
Trial: Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Smal
May 11, 2026
dark_pool
Dark Pool: PFE — 23.4M shares, 175,172 trades
Week starting 2026-05-11. Total ATS volume: 23,431,429 shares across 175,172 trades.
May 8, 2026
short_interest
FTD: PFE — 35,039 shares ($0.9M) failed to deliver
Settlement: 20260508, Price: $26.48, FTD Value: $927,832.72, PFIZER INC;COM USD0.05
May 7, 2026
short_volume
Short Volume: PFE — 56.2% short (11.7M / 20.8M)
Short: 11,688,209 | Exempt: 61,638 | TRF Vol: 20,789,801 | Short Ratio: 56.2% | Off-exchange volume (dark pool + OTC)
May 7, 2026
short_interest
FTD: PFE — 99,658 shares ($2.6M) failed to deliver
Settlement: 20260507, Price: $26.53, FTD Value: $2,643,926.74, PFIZER INC;COM USD0.05